Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Evotec

BATS-CHIXE:EVTD
Snowflake Description

Reasonable growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EVTD
BATS-CHIXE
€3B
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Evotec has significant price volatility in the past 3 months.
EVTD Share Price and Events
7 Day Returns
2.7%
BATS-CHIXE:EVTD
19.9%
GB Life Sciences
10%
GB Market
1 Year Returns
-16%
BATS-CHIXE:EVTD
-15.8%
GB Life Sciences
-23%
GB Market
EVTD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Evotec (EVTD) 2.7% -5.1% -11.4% -16% 117.1% 437.8%
GB Life Sciences 19.9% -20.4% -32% -15.8% -16.1% -24.9%
GB Market 10% -17.6% -27.3% -23% -24.2% -21.8%
1 Year Return vs Industry and Market
  • EVTD matched the Life Sciences industry (-15.8%) over the past year.
  • EVTD outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23% over the past year.
Price Volatility
EVTD
Industry
5yr Volatility vs Market

EVTD Value

 Is Evotec undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Evotec to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Evotec.

BATS-CHIXE:EVTD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.5%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:EVTD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.033 (1 + (1- 30%) (15.12%))
1.095
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.095 * 5.44%)
6.49%

Discounted Cash Flow Calculation for BATS-CHIXE:EVTD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Evotec is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:EVTD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.49%)
2020 46.30 Analyst x2 43.48
2021 31.67 Analyst x3 27.93
2022 72.70 Analyst x1 60.20
2023 94.67 Est @ 30.22% 73.62
2024 114.85 Est @ 21.31% 83.87
2025 132.16 Est @ 15.08% 90.64
2026 146.32 Est @ 10.71% 94.23
2027 157.53 Est @ 7.66% 95.27
2028 166.23 Est @ 5.52% 94.40
2029 172.91 Est @ 4.02% 92.22
Present value of next 10 years cash flows €755.00
BATS-CHIXE:EVTD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €172.91 × (1 + 0.53%) ÷ (6.49% – 0.53%)
€2,917.36
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €2,917.36 ÷ (1 + 6.49%)10
€1,555.85
BATS-CHIXE:EVTD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €755.00 + €1,555.85
€2,310.85
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €2,310.85 / 150.98
€15.31
BATS-CHIXE:EVTD Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:EVTD represents 1.00245x of XTRA:EVT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.00245x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 15.31 x 1.00245
€15.34
Value per share (EUR) From above. €15.34
Current discount Discount to share price of €20.48
= -1 x (€20.48 - €15.34) / €15.34
-33.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Evotec is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Evotec's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Evotec's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:EVTD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €0.25
XTRA:EVT Share Price ** XTRA (2020-03-31) in EUR €20.43
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 48.4x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 747 Publicly-Listed Companies 12.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Evotec.

BATS-CHIXE:EVTD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:EVT Share Price ÷ EPS (both in EUR)

= 20.43 ÷ 0.25

80.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evotec is overvalued based on earnings compared to the Europe Life Sciences industry average.
  • Evotec is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Evotec's expected growth come at a high price?
Raw Data
BATS-CHIXE:EVTD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 80.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
24.2%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 526 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:EVTD PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 80.35x ÷ 24.2%

3.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evotec is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Evotec's assets?
Raw Data
BATS-CHIXE:EVTD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €3.17
XTRA:EVT Share Price * XTRA (2020-03-31) in EUR €20.43
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 1.88x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,322 Publicly-Listed Companies 1.08x
BATS-CHIXE:EVTD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:EVT Share Price ÷ Book Value per Share (both in EUR)

= 20.43 ÷ 3.17

6.45x

* Primary Listing of Evotec.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evotec is overvalued based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess Evotec's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Evotec has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EVTD Future Performance

 How is Evotec expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
24.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Evotec expected to grow at an attractive rate?
  • Evotec's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Evotec's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Evotec's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:EVTD Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:EVTD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 24.2%
BATS-CHIXE:EVTD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 9.6%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 43.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:EVTD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:EVTD Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 739 159 1
2023-12-31 634 136 86 2
2022-12-31 626 121 76 2
2021-12-31 554 112 57 4
2020-12-31 470 83 29 3
2020-03-31
BATS-CHIXE:EVTD Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 446 42 38
2019-09-30 419 29 61
2019-06-30 404 74 77
2019-03-31 398 139 94
2018-12-31 375 156 84
2018-09-30 370 135 63
2018-06-30 338 80 31
2018-03-31 294 19 20
2017-12-31 264 11 23
2017-09-30 215 64 28
2017-06-30 193 73 35
2017-03-31 178 74 36

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Evotec's earnings are expected to grow significantly at over 20% yearly.
  • Evotec's revenue is expected to grow by 9.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:EVTD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Evotec Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:EVTD Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.67 0.67 0.67 1.00
2023-12-31 0.52 0.52 0.52 1.00
2022-12-31 0.45 0.50 0.39 2.00
2021-12-31 0.35 0.40 0.28 3.00
2020-12-31 0.24 0.34 0.12 3.00
2020-03-31
BATS-CHIXE:EVTD Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 0.25
2019-09-30 0.41
2019-06-30 0.52
2019-03-31 0.63
2018-12-31 0.57
2018-09-30 0.43
2018-06-30 0.21
2018-03-31 0.13
2017-12-31 0.16
2017-09-30 0.20
2017-06-30 0.25
2017-03-31 0.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Evotec is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Evotec's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Evotec has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EVTD Past Performance

  How has Evotec performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Evotec's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Evotec has delivered over 20% year on year earnings growth in the past 5 years.
  • Evotec's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Evotec's 1-year earnings growth is negative, it can't be compared to the Europe Life Sciences industry average.
Earnings and Revenue History
Evotec's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Evotec Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:EVTD Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 446.44 38.07 65.76 58.43
2019-09-30 418.68 61.50 62.46 55.96
2019-06-30 403.62 76.97 59.77 54.89
2019-03-31 397.62 93.77 58.45 45.36
2018-12-31 375.41 84.17 57.01 35.62
2018-09-30 370.31 62.92 53.84 26.04
2018-06-30 338.31 30.79 53.71 19.09
2018-03-31 294.49 19.66 48.36 17.58
2017-12-31 263.77 23.48 42.38 17.61
2017-09-30 215.43 28.35 38.55 17.83
2017-06-30 193.39 34.78 31.05 17.62
2017-03-31 177.94 35.56 28.96 18.37
2016-12-31 164.51 27.53 27.01 18.11
2016-09-30 160.11 17.98 23.88 17.64
2016-06-30 148.17 6.27 24.54 18.87
2016-03-31 143.61 16.83 25.42 18.90
2015-12-31 127.68 16.52 25.17 18.34
2015-09-30 118.76 11.69 24.24 16.72
2015-06-30 104.37 11.01 21.50 14.63
2015-03-31 93.43 -4.04 18.75 13.27
2014-12-31 89.50 -6.98 17.99 12.40
2014-09-30 84.55 -28.56 17.06 11.37
2014-06-30 89.33 -25.28 17.30 11.13
2014-03-31 86.49 -26.59 17.03 10.31
2013-12-31 85.94 -25.43 16.60 9.66
2013-09-30 83.38 -9.92 16.36 9.72
2013-06-30 81.91 -3.78 16.45 9.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Evotec has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Evotec used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • Evotec's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Evotec's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Evotec has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EVTD Health

 How is Evotec's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Evotec's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Evotec is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Evotec's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Evotec's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Evotec Company Filings, last reported 3 months ago.

BATS-CHIXE:EVTD Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 477.03 331.23 321.66
2019-09-30 462.63 318.09 283.19
2019-06-30 439.13 333.38 342.26
2019-03-31 448.26 122.70 142.10
2018-12-31 424.88 109.75 149.88
2018-09-30 390.26 146.51 169.08
2018-06-30 353.06 154.98 110.23
2018-03-31 339.29 181.14 91.77
2017-12-31 331.92 188.06 91.95
2017-09-30 318.28 169.71 101.75
2017-06-30 314.21 7.82 190.60
2017-03-31 313.33 8.17 187.24
2016-12-31 213.94 28.61 127.86
2016-09-30 193.82 14.80 122.70
2016-06-30 186.47 18.20 119.72
2016-03-31 182.68 22.62 124.66
2015-12-31 187.09 22.94 134.96
2015-09-30 177.38 22.93 139.66
2015-06-30 180.55 22.56 142.01
2015-03-31 163.33 22.23 97.68
2014-12-31 158.38 21.55 88.96
2014-09-30 155.63 21.41 91.44
2014-06-30 156.92 20.61 86.64
2014-03-31 155.96 18.16 91.67
2013-12-31 158.97 17.22 97.25
2013-09-30 177.69 17.27 86.19
2013-06-30 146.70 17.31 57.23
  • Evotec's level of debt (69.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (13.6% vs 69.4% today).
  • Debt is not well covered by operating cash flow (12.7%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 14.7x coverage).
X
Financial health checks
We assess Evotec's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Evotec has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EVTD Dividends

 What is Evotec's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Evotec dividends. Estimated to be 0% next year.
If you bought €2,000 of Evotec shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Evotec's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Evotec's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:EVTD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 629 Stocks 6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:EVTD Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31 0.00 1.00
2022-12-31 0.00 1.00
2021-12-31
2020-12-31
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Evotec has not reported any payouts.
  • Unable to verify if Evotec's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Evotec's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Evotec has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Evotec's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Evotec's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Evotec afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Evotec has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EVTD Management

 What is the CEO of Evotec's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Werner Lanthaler
COMPENSATION €1,779,000
AGE 51
TENURE AS CEO 7 years
CEO Bio

Dr. Werner Lanthaler, MBA, MPA, has been the Chief Executive Officer of Evotec AG since March 2009 and serves as its Member of Management Board. Dr. Lanthaler has an outstanding track record of building and growing life sciences companies. Dr. Lanthaler served as the Chief Executive Officer of Evotec AG from March 6, 2009 to October 4, 2012. Dr. Lanthaler served as Treasurer of Intercell USA Inc. (formerly Iomai Corporation) since 2008. He served as the Chief Financial Officer of Intercell Biomedical Research & Development AG from September 2001 to March 2009 and as its Member of Management Board until March 6, 2009. He was responsible for the departments of Finance, Administration, Human Resources, Investor Relations and Marketing & Sales at Intercell. He has considerable experience working in the labor and capital markets of the US, South America and Europe. He served as Chief Financial Officer at Intercell AG from 2000 to 2009. Dr. Lanthaler played a pivotal role in many of Intercell 's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, its acquisitions and strategic pharma partnerships, as well as its Initial Public Offering in 2005. He served as the Head of Marketing and Communications of the Federation of Austrian Industry from 1998 to 2000. He served as a Senior Management Consultant of McKinsey & Company International from 1995 to 1998. He serves as Vice Chairperson at argenx SE. He serves as a Director of Topas Therapeutics GmbH. He has been Non-Executive Director of argenx SE since July 9, 2014. He was the Interim Chairman of the Supervisory Board of Topas Therapeutics GmbH. He served as Supervisory Director of argenx SE since April 08, 2014. Dr. Lanthaler served as Deputy Chairman of Supervisory Board at Evotec (Göttingen) AG (alternative name DeveloGen AG). He has been Director of AC Immune SA since July 6, 2018. He served as a Director of Pantec Biosolutions AG. He served as a Director of BioXell S.p.A. since April 2002. He served as a Director of Intercell USA, Inc. since 2008. He is also an Author and co-author of a wide range of books and articles. Dr. Lanthaler holds a Ph. D. in business administration from the Vienna University of Economics and Business Administration. He also holds a Master's Degree in Public Administration and a Master’s Degree in Business Administration from Harvard University. He has a Degree in Psychology and MD from ludwig Maximilians University. He holds a PhD from Max Planck Institute of Psychiatry.

CEO Compensation
  • Werner's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Werner's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Evotec management team in years:

3.7
Average Tenure
53
Average Age
  • The tenure for the Evotec management team is about average.
Management Team

Werner Lanthaler

TITLE
CEO & Member of Management Board
COMPENSATION
€2M
AGE
51
TENURE
7 yrs

Enno Spillner

TITLE
CFO & Member of Management Board
COMPENSATION
€712K
AGE
49
TENURE
3.7 yrs

Cord Dohrmann

TITLE
Chief Scientific Officer & Member of Management Board
COMPENSATION
€838K
AGE
55
TENURE
9.4 yrs

Craig Johnstone

TITLE
COO, Head of EVT Execute segment & Member of Management Board
TENURE
1.2 yrs

Anja Bosler

TITLE
Principal Accounting Officer and Senior Vice President of Group Accounting

Gabriele Hansen

TITLE
Vice President of Corporate Communications

Monika Conradt

TITLE
Global Head of Human Resources
TENURE
3.7 yrs

Ian Hunneyball

TITLE
Senior Vice President of Programme Management & Clinical Operations
COMPENSATION
€116K
AGE
69

Dave Hallet

TITLE
Executive Vice President

Erich Greiner

TITLE
Chief Innovation Officer
AGE
53
Board of Directors Tenure

Average tenure and age of the Evotec board of directors in years:

1.7
Average Tenure
57
Average Age
  • The average tenure for the Evotec board of directors is less than 3 years, this suggests a new board.
Board of Directors

Wolfgang Plischke

TITLE
Chairman of Supervisory Board
AGE
68
TENURE
5.7 yrs

Iris Löw-Friedrich

TITLE
Vice Chairperson of the Supervisory Board
AGE
59
TENURE
0.7 yrs

Roland Sackers

TITLE
Member of the Supervisory Board
AGE
50
TENURE
0.7 yrs

Mario Polywka

TITLE
Member of the Supervisory Board
COMPENSATION
€846K
AGE
56
TENURE
0.7 yrs

Elaine Sullivan

TITLE
Member of Supervisory Board
AGE
58
TENURE
4.7 yrs

Michael Shalmi

TITLE
Member of Supervisory Board
AGE
54
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Evotec's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Evotec has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EVTD News

Simply Wall St News

EVTD Company Info

Description

Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. The EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has collaboration with Indivumed GmbH to identify new therapeutic targets for the treatment of colorectal cancer; and a partnership with Celmatix Inc. to develop pre-clinical programs in prevalent but underserved conditions affecting women's reproductive health. The company was founded in 1993 and is headquartered in Hamburg, Germany.

Details
Name: Evotec SE
EVTD
Exchange: BATS-CHIXE
Founded: 1993
€3,061,844,223
150,978,512
Website: http://www.evotec.com
Address: Evotec SE
Manfred Eigen Campus,
Essener Bogen 7,
Hamburg,
Hamburg, 22419,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA EVT Common Stock XETRA Trading Platform DE EUR 10. Nov 1999
OTCPK EVOT.F Common Stock Pink Sheets LLC US USD 10. Nov 1999
DB EVT Common Stock Deutsche Boerse AG DE EUR 10. Nov 1999
LSE 0IRF Common Stock London Stock Exchange GB EUR 10. Nov 1999
SWX EVT Common Stock SIX Swiss Exchange CH CHF 10. Nov 1999
WBAG EVT Common Stock Wiener Boerse AG AT EUR 10. Nov 1999
ETLX EVT Common Stock Eurotlx IT EUR 10. Nov 1999
BATS-CHIXE EVTD Common Stock BATS 'Chi-X Europe' GB EUR 10. Nov 1999
OTCPK EVTC.Y SPON ADS EACH REP 2 ORD SHS Pink Sheets LLC US USD 05. May 2008
DB EVTA SPON ADS EACH REP 2 ORD SHS Deutsche Boerse AG DE EUR 05. May 2008
XTRA EVTA SPON ADS EACH REP 2 ORD SHS XETRA Trading Platform DE EUR 05. May 2008
Number of employees
Current staff
Staff numbers
3,030
Evotec employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 21:09
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.